Biosig Technologies (BSGM) Rating Increased to Buy at Zacks Investment Research

Biosig Technologies (OTCMKTS:BSGM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday. The firm presently has a $1.50 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 5.01% from the company’s previous close.

According to Zacks, “BioSig Technologies, Inc. is a medical device company which is engaged in developing technology platform to improve cardiac recording during electrophysiology studies and ablation procedures. “

Separately, Chardan Capital restated a “buy” rating on shares of Biosig Technologies in a research report on Sunday, October 1st.

Biosig Technologies (OTCMKTS:BSGM) traded down $0.02 during midday trading on Friday, reaching $1.43. 12,968 shares of the company were exchanged, compared to its average volume of 48,832. Biosig Technologies has a twelve month low of $1.20 and a twelve month high of $2.00.

COPYRIGHT VIOLATION WARNING: “Biosig Technologies (BSGM) Rating Increased to Buy at Zacks Investment Research” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at

Biosig Technologies Company Profile

BioSig Technologies, Inc is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System.

Get a free copy of the Zacks research report on Biosig Technologies (BSGM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Biosig Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies Inc. and related companies with's FREE daily email newsletter.

Leave a Reply